Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892379 · ClinicalTrials.gov registry record · Phase 1
A Study of HS-20110 in Participants With Advanced Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Hansoh BioMedical R&D Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 475
- Enrollment target
- 6
- Study locations
NCT06892379: Recruiting Phase 1 study of Solid Tumors, sponsored by Hansoh BioMedical R&D Company.
NCT06892379 is a Phase 1 study of Solid Tumors that is actively recruiting participants, run by Hansoh BioMedical R&D Company. The registered enrollment target is 475 participants, above the 281-participant average among 125 other Solid Tumors trials with a reported enrollment target (69% higher). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06892379, a Phase 1 study of Solid Tumors, is actively recruiting participants, sponsored by Hansoh BioMedical R&D Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 475 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
Conditions Studied
Interventions
- DRUG HS-20110 (Phase Ia：Dose escalation )
- DRUG HS-20110 (Phase Ib:Dose expansion )
Study Locations (6)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- NEXT Dallas - Irving
- NEXT Oncology - San Antonio
Florida
- BRCR Medical Center INC - Tamarac
Virginia
- NEXT Virginia - Fairfax
Guangdong
- SUN YAT-SEN University Cancer Center - Guangzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 1 |
What NCT06892379 shows while recruiting
NCT06892379 is an interventional study that assigns participants to a tested intervention. The registered 475 participants enrollment target is mid-sized for trials with a published cap, above the 281-participant average among 125 other Solid Tumors trials with a reported enrollment target (69% higher).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which HS-20110 (Phase Ia：Dose escalation ) is the first listed.
NCT06892379 lists 6 locations in 4 states (Texas, Florida, Virginia).
Frequently Asked Questions
What is clinical trial NCT06892379 about?
NCT06892379 is a clinical study titled "A Study of HS-20110 in Participants With Advanced Solid Tumors". This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
What is the current status of trial NCT06892379?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 475 participants. The study started on 2025-02-26. Estimated completion is 2027-09-30.
What conditions does trial NCT06892379 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT06892379?
The interventions under investigation include: HS-20110 (Phase Ia：Dose escalation ) (DRUG), HS-20110 (Phase Ib:Dose expansion ) (DRUG).
Who is sponsoring clinical trial NCT06892379?
This trial is sponsored by Hansoh BioMedical R&D Company, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06892379 being conducted?
This trial has 6 study locations across Florida, Texas, Virginia, Guangdong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06892379's enrollment target sits among peer trials
475 10th of 125 higher than 116 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
- NCT05451303 · 475 participants
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
- NCT06754046 · 476 participants · NA
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
- NCT05624996 · 474 participants · Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI